Journal
JOURNAL OF HEART AND LUNG TRANSPLANTATION
Volume 32, Issue 2, Pages 141-156Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.healun.2012.12.004
Keywords
mechanical support; ventricular assist devices; INTERMACS; advanced heart failure; destination therapy
Funding
- NHLBI [HHSN268201100025C]
Ask authors/readers for more resources
The 5th annual report of the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) summarizes and analyzes the first 6 years of patient and data collection. The current analysis includes more than 6000 patients and updated risk factors for continuous flow pumps. Among continuous flow pumps, actuarial survival is 80% at 1 year and 70% at 2 years. Quality of life indicators are generally favorable and adverse event burden will likely influence patient selections of advanced heart failure therapies. J Heart Lung Transplant 2013;32:141-156 (c) 2013 International Society for Heart and Lung Transplantation. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available